Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Cardiac amyloidosis (CA) and hypertrophic cardiomyopathy often manifest with overlapping clinical features, making diagnosis and management challenging.
Case Summary: We describe a 79-year-old man presenting with exertional dyspnea and presyncope who was diagnosed with transthyretin CA with left ventricular outflow tract (LVOT) obstruction and was treated with concurrent mavacamten and tafamidis.
Discussion: There is substantial overlap in the clinical phenotypes of hypertrophic cardiomyopathy and CA, and the presence of hemodynamically significant LVOT does not exclude the possibility of CA as an underlying diagnosis. Endomyocardial biopsy may be required when noninvasive testing is ambiguous or in the presence of overlapping disease features.
Take-home Messages: Hemodynamically significant LVOT obstruction is a rare but clinically relevant manifestation of CA that may lead to diagnostic ambiguity and difficult management decisions. Tafamidis and mavacamten can be used safely in combination to provide symptom relief and slow disease progression in obstructive transthyretin CA.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jaccas.2025.104495 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Concurrent Use of Tafamidis and Mavacamten for Transthyretin Cardiac Amyloidosis With Severe Outflow Tract Obstruction.
JACC Case Rep
August 2025
Division of Cardiology, Johns Hopkins Medical Center, Baltimore, Maryland, USA. Electronic address:
Background: Cardiac amyloidosis (CA) and hypertrophic cardiomyopathy often manifest with overlapping clinical features, making diagnosis and management challenging.
Case Summary: We describe a 79-year-old man presenting with exertional dyspnea and presyncope who was diagnosed with transthyretin CA with left ventricular outflow tract (LVOT) obstruction and was treated with concurrent mavacamten and tafamidis.
Discussion: There is substantial overlap in the clinical phenotypes of hypertrophic cardiomyopathy and CA, and the presence of hemodynamically significant LVOT does not exclude the possibility of CA as an underlying diagnosis.
Hypertrophic Cardiomyopathy and Phenocopies: New Therapies for Old Diseases-Current Evidence and Future Perspectives.
J Clin Med
June 2025
Department of Clinical, Internal, Anaesthesiology and Cardiovascular Sciences, Sapienza University of Rome, 00161 Rome, Italy.
The hypertrophic cardiomyopathy (HCM) clinical phenotype includes sarcomeric HCM, which is the most common form of inherited cardiomyopathy with a population prevalence of 1:500, and phenocopies such as cardiac amyloidosis and Anderson-Fabry disease, which are considered rare diseases. Identification of cardiac and non-cardiac red flags in the context of multi-organ syndrome, multimodality imaging, including echocardiography, cardiac magnetic resonance, and genetic testing, has a central role in the diagnostic pathway. Identifying the specific disease underlying the hypertrophic phenotype is very important since many disease-modifying therapies are currently available, and phase 3 trials for new treatments have been completed or are ongoing.
View Article and Find Full Text PDF[Precision medicine in the diagnostics and treatment of cardiomyopathies : State of the art].
Herz
April 2025
Precision Digital Health, Department of Internal Medicine III, University of Heidelberg, Heidelberg, Deutschland.
Cardiomyopathies (CMP) comprise a group of heterogeneous heart muscle diseases that have molecular genetic causes and cannot be adequately explained by other cardiovascular diseases. The diagnosis and treatment of CMPs have made significant progress in recent decades, which is reflected in novel specific cardiomyopathy guidelines of the European Society of Cardiology (ESC) published in 2023. A patient-centered approach combines multimodal diagnostics, such as echocardiography, magnetic resonance imaging, genetic testing and biopsy to enable precise etiological classification and thus personalized treatment.
View Article and Find Full Text PDFEarly genetic screening and cardiac intervention in patients with cardiomyopathies in a multidisciplinary clinic.
ESC Heart Fail
June 2025
Division of Cardiology, Department of Medicine, Mazankowski Alberta Heart Institute, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.
Article Synopsis
- The study aims to investigate how early assessment and genetic counseling in a multidisciplinary Cardiomyopathy Clinic can enhance patient outcomes and reduce the severity of heart failure.
- A total of 421 patients with various types of cardiomyopathy participated, with a significant portion undergoing genetic testing that revealed a notable incidence of pathogenic variants.
- Follow-up showed increased use of heart failure medications and improved heart function, indicated by a rise in left ventricular ejection fraction (LVEF) and a decrease in left ventricular mass index (LVMI) among patients with dilated cardiomyopathy (DCM).
2024 update in heart failure.
ESC Heart Fail
February 2025
Institute of Cardiology, ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy.
Article Synopsis
- The 2023 ESC update to the HF guidelines emphasizes two new drugs, SGLT2 inhibitors and finerenone, for preventing heart failure in patients with diabetic chronic kidney disease, and supports the use of SGLT2 inhibitors across all levels of left ventricular ejection fraction.
- Quadruple therapy in patients with reduced ejection fraction is beneficial, and the "high-intensity care" approach, involving rapid medication adjustments and close monitoring post-acute heart failure, leads to better outcomes.
- Recent trials suggest that semaglutide can improve quality of life and physical activity in obese patients with preserved ejection fraction, while findings on additional diuretics and therapies, especially for different